Steve Brozak
Stock Analyst at WBB Securities
(0.96)
# 3,951
Out of 5,113 analysts
9
Total ratings
33.33%
Success rate
-6.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steve Brozak
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OMER Omeros | Reiterates: Strong Buy | $45 | $12.67 | +255.17% | 3 | Oct 15, 2025 | |
| CELU Celularity | Upgrades: Buy | $6 | $1.29 | +366.20% | 2 | Sep 9, 2025 | |
| MRKR Marker Therapeutics | Reiterates: Strong Buy | $13 | $1.80 | +594.44% | 1 | Apr 1, 2025 | |
| RDHL RedHill Biopharma | Downgrades: Buy | $17,000 → $16,000 | $1.33 | +1,202,907.52% | 3 | May 28, 2021 |
Omeros
Oct 15, 2025
Reiterates: Strong Buy
Price Target: $45
Current: $12.67
Upside: +255.17%
Celularity
Sep 9, 2025
Upgrades: Buy
Price Target: $6
Current: $1.29
Upside: +366.20%
Marker Therapeutics
Apr 1, 2025
Reiterates: Strong Buy
Price Target: $13
Current: $1.80
Upside: +594.44%
RedHill Biopharma
May 28, 2021
Downgrades: Buy
Price Target: $17,000 → $16,000
Current: $1.33
Upside: +1,202,907.52%